Nathalie Rioux

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8615014/publications.pdf

Version: 2024-02-01

27	1,514	516710 16	477307 29
papers	citations	h-index	g-index

29	29	29	2615
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	A selective inhibitor of PRMT5 with in vivo and in vitro potency in MCL models. Nature Chemical Biology, 2015, 11, 432-437.	8.0	442
2	Structure and Property Guided Design in the Identification of PRMT5 Tool Compound EPZ015666. ACS Medicinal Chemistry Letters, 2016, 7, 162-166.	2.8	113
3	EPZ011989, A Potent, Orally-Available EZH2 Inhibitor with Robust in Vivo Activity. ACS Medicinal Chemistry Letters, 2015, 6, 491-495.	2.8	107
4	Aryl Pyrazoles as Potent Inhibitors of Arginine Methyltransferases: Identification of the First PRMT6 Tool Compound. ACS Medicinal Chemistry Letters, 2015, 6, 655-659.	2.8	105
5	H3B-6527 Is a Potent and Selective Inhibitor of FGFR4 in FGF19-Driven Hepatocellular Carcinoma. Cancer Research, 2017, 77, 6999-7013.	0.9	100
6	Preclinical Profile of BI 224436, a Novel HIV-1 Non-Catalytic-Site Integrase Inhibitor. Antimicrobial Agents and Chemotherapy, 2014, 58, 3233-3244.	3.2	88
7	Discovery of Selective Estrogen Receptor Covalent Antagonists for the Treatment of ERÎ±WT and ERÎ±MUT Breast Cancer. Cancer Discovery, 2018, 8, 1176-1193.	9.4	81
8	Novel Oxindole Sulfonamides and Sulfamides: EPZ031686, the First Orally Bioavailable Small Molecule SMYD3 Inhibitor. ACS Medicinal Chemistry Letters, 2016, 7, 134-138.	2.8	71
9	The induction of cyclooxygenase-1 by a tobacco carcinogen in U937 human macrophages is correlated to the activation of NF-Î¹B. Carcinogenesis, 2000, 21, 1745-1751.	2.8	70
10	Inhibition of Lung Tumorigenesis by Nsaids: A Working Hypothesis. Experimental Lung Research, 1998, 24, 605-615.	1.2	66
11	Results of a Clinical Trial of H3B-8800, a Splicing Modulator, in Patients with Myelodysplastic Syndromes (MDS), Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic Leukemia (CMML). Blood, 2019, 134, 673-673.	1.4	66
12	Small molecule inhibitors and CRISPR/Cas9 mutagenesis demonstrate that SMYD2 and SMYD3 activity are dispensable for autonomous cancer cell proliferation. PLoS ONE, 2018, 13, e0197372.	2.5	45
13	Physiologically Based Pharmacokinetic Modeling in Pediatric Oncology Drug Development. Drug Metabolism and Disposition, 2016, 44, 934-943.	3.3	26
14	Structure-based design of novel HCV NS5B thumb pocket 2 allosteric inhibitors with submicromolar gt1 replicon potency: Discovery of a quinazolinone chemotype. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 4132-4140.	2.2	19
15	Aligning Potency and Pharmacokinetic Properties for Pyridine-Based NCINIs. ACS Medicinal Chemistry Letters, 2016, 7, 797-801.	2.8	18
16	Nonclinical pharmacokinetics and in vitro metabolism of H3B-6545, a novel selective ERÎ± covalent antagonist (SERCA). Cancer Chemotherapy and Pharmacology, 2019, 83, 151-160.	2.3	18
17	A high throughputin vitromrp2 assay to predictin vivobiliary excretion. Xenobiotica, 2012, 42, 157-163.	1.1	14
18	Species differences in metabolism of EPZ015666, an oxetane-containing protein arginine methyltransferase-5 (PRMT5) inhibitor. Xenobiotica, 2016, 46, 268-277.	1.1	14

#	Article	IF	Citations
19	Assessment of CYP3Aâ€mediated drugâ€“drug interaction potential for victim drugs using an in vivo rat model. Biopharmaceutics and Drug Disposition, 2013, 34, 396-401.	1.9	11
20	A membrane vesicle-based assay to enable prediction of human biliary excretion. Xenobiotica, 2013, 43, 915-919.	1.1	8
21	Structural and Kinetic Characterization of a Novel N-acetylated Aliphatic Amine Metabolite of the PRMT Inhibitor, EPZ011652. Drug Metabolism and Disposition, 2015, 43, 936-943.	3.3	7
22	Identification of a First-in-Class PRMT5 Inhibitor with Potent in Vitro and in Vivo Activity in Preclinical Models of Mantle Cell Lymphoma. Blood, 2014, 124, 438-438.	1.4	6
23	Abstract DDT01-04: Discovery and development of H3B-6545: A novel, oral, selective estrogen receptor covalent antagonist (SERCA) for the treatment of breast cancer. Cancer Research, 2017, 77, DDT01-04-DDT01-04.	0.9	5
24	Effect of a high-fat meal on the relative bioavailability of H3B-6527, a novel FGFR4 inhibitor, in healthy volunteers. Cancer Chemotherapy and Pharmacology, 2019, 83, 91-96.	2.3	3
25	Metabolic disposition of H3B-8800, an orally available small-molecule splicing modulator, in rats, monkeys, and humans. Xenobiotica, 2020, 50, 1101-1114.	1.1	3
26	A simplified approach to predict CYP3A-mediated drugâ€“drug interactions at early drug discovery: validation with clinical data. Xenobiotica, 2013, 43, 592-597.	1.1	2
27	A strategy to reduce biliary clearance in early drug discovery. Journal of Pharmacological and Toxicological Methods, 2013, 68, 346-348.	0.7	1